Business
Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative
About this update from Design Therapeutics, Inc.
[{"type":"text","content":"CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company’s first clinical trial planned to begin in the first half of 2022. “I am thrilled to welcome Jae to Design, particularly as we prepare to embark on the important transition to a clinical stage company and initiation of our Phase 1 clinical trial in patients with Friedreich ataxia,” said João Siffert, M.D., president and chief executive officer of Design Therapeutics. “Jae has had an illustrious career spanning from his time in academic medicine to building broad clinical-stage pipelines, including playing an instrumental role in the approval of a first-in-class gene silencing therapy during his time at Alnylam. He will be invaluable to the future of Design and we look forward to his contributions and insights as we continue on our path of conducting breakthrough genomic medicine drug discovery and advancing novel small molecule drug candidates from the research bench into the clinic.” “Design is at the leading edge of a new generation of biotech companies that are leveraging the known genetic drivers of monogenic disorders to address inherited nucleotide repeat diseases,” said Dr. Kim. “I am highly compelled by Design’s approach to treating the root cause of inherited degenerative disorders; the validating preclinical data demonstrating the ability of its FA GeneTAC™ molecules to dial up FXN expression in an animal model and across multiple human cell systems provide compelling evidence for the potential to treat the cause of FA. Further, Design’s diverse portfolio of GeneTAC™ molecules have the potential to offer a disease-modifying treatment to patients with few therapeutic options across a number of devastating degenerative disorders. I am excited to join this remarkably talented team and to help change the lives of patients and their families.” Dr. Kim joins Design from Avidity Biosciences, where he served as chief medical officer until August 2021 and led the advancement of the company’s pipeline, including the initiation of the company’s first-in-human study, a Phas...